The new report, based on data from the U.S. Bureau of Labor Statistics, once again highlights the fact that cardiology is associated with high demand and high compensation in today's market. 

The American College of Cardiology has developed a helpful calculator that allows cardiologists and practice managers to estimate just how much the proposed 2023 MPFS could impact their practice.

Affera’s portfolio includes interventional solutions such as the Affera Prism-1 mapping and navigation platform, designed to help electrophysiologists diagnose heart rhythm issues, and the Sphere-9 cardiac ablation catheter. 

A new report by data analysts highlights a trend many in cardiology have already noticed: the continued prominence of AI-powered solutions designed to diagnose and treat CVD. 

While current guidelines endorse screening for people aged 65 and above, a massive simulation published in JAMA Health Forum suggests that cost-effectiveness may extend to even younger age groups.

After finding success in Europe, the company is focused on gaining FDA approval for its Trilogy Heart Valve System and launching the device in the United States.